• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,264.33 736.38
( 0.97%)
Global Indices
Nasdaq
51,233.54 363.79
(0.72%)
Dow Jones
7,453.14 37.84
(0.51%)
Hang Seng
69,318.21 3,298.17
(5.00%)
Nikkei 225
10,460.24 156.36
(1.52%)
Forex
USD-INR
95.49 0.16
(0.17%)
EUR-INR
110.25 0.17
(0.15%)
GBP-INR
127.74 0.15
(0.12%)
JPY-INR
0.60 0.00
(0.21%)

EQUITY - MARKET SCREENER

Aurobindo Pharma Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524804
INE406A01037
391.1437121
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AUROPHARMA
35.21
85508.52
EPS(TTM)
Face Value()
Div & Yield %
41.81
1
0.27
 

pakka ltd
Waaree Renewable Tech secures EPC contract for 300 MW solar project
Jun 08,2026
The contract pertains to a 300 MW/450 MWp ground-mounted solar power project and includes operation and maintenance (O&M) services for a period of two years.

According to the company, the project is scheduled for completion during FY2026-27, in line with the terms of the contract. The aggregate order size stands at 300 MW/450 MWp.

Waaree Renewable Technologies clarified that SPPL is a subsidiary of the company and that the contract therefore qualifies as a related-party transaction. The company added that its promoter and promoter group entities have an interest in the awarding entity through this subsidiary relationship.

Waaree Renewable Technologies (WRTL) is a subsidiary company of the Waaree Group and is spearheading the Solar EPC business. We are also a solar developer that finances, constructs, owns, and operates solar projects. Headquartered in Mumbai, we operate across geographies, focusing on long-term investments within the commercial and industrial customer segments.

The company’s consolidated net profit surged 124.74% to Rs 120.19 crore in Q3 FY26 as against Rs 53.48 crore in Q3 FY25. Revenue from operations zoomed 136.18% year on year (YoY) to Rs 851.06 crore in Q3 FY26 over Q3 FY25.

The counter slipped 2.04% to Rs 950.65 on the BSE.